IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Diagnosis, treatment and management of hereditary nonpolyposis colorectal cancer (HNPCC).

[1]Gadade pooja Nandkumar,[2]Dahifale Dnyaneshwari Raghunath
[1,2]Pravara Rural college of pharmacy Loni, Maharashtra , India

Abstract

Hereditary nonpolyposis colorectal cancer (HNPPCC) may be a commonplace familial cancer that's one of autosomal overwhelming acquired illnesses. Since endometrial cancer happens as often as possible in ladies with HNPCC, a few endometrial cancers, like HNPCC, are familial cancers caused by changes within the DNA bungle repair (MMR) quality. It is observed that to get it the clinical pathology of familial endometrial cancer associated with HNPCC, we examined the family history of 385 endometrial cancer patients and found that 0.5% of endometrial cancer patients met the unused symptomatic criteria for her HNPCC. It turned out to meet. Atomic and organic analyzes found microsatellite insecurity in 30.8% of endometrial think about cancers and germline mutations in MMR qualities in 8.3% of . These comes about show that there's a near relationship between MMR quality changes and the improvement of endometrial cancer. To superior get it the clinical pathology of HNPCC-associated familial endometrial cancer, it is vital for gynecologists to conduct large-scale multicenter considers that incorporate a complete family history.this study contains the diagnosis, surveillance and treatment of the HNPCC.

Key words: hereditary non-polyposis colorectal cancer, Lynch syndrome, surveillance, Management, Treatment, Diagnosis.

Introduction

The primary known genetic non-polyposis colorectal cancer (HNPCC) family, "family G", was Described by the Michigan pathologist Aldred Scott Warthin in 1913. Family G was returned to By Henry T Lynch in 1971. Lynch et al portrayed two innate colon cancer disorders: Lynch Disorder where colon cancer was the as it were happening danger; and Lynch disorder 2, which Was characterised by a tall chance of colorectal cancer (CRC) but too of other extracolonic Cancers, particularly cancer of the endometrium, stomach, ovary, urinary tract, and other Gastrointestinal cancers.(1-4)In 1996, approximately 133,500 new cases of colorectal cancer (CRC) were diagnosed. This Cancer, also known as hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome (LS), is characterized by a strong predisposition to colorectal and endometrial cancer, as well as A weaker predisposition to cancers in many other organs(5). LS is caused by defects in one of The DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6, or PMS2, representing the MMR-Deficient subgroup of HNPCC.(6) It's among the most prevalent hereditary cancer syndromes in Humans, with the highest reported population frequency to date being 1 in 226 individuals.(7)

Responsible genes in HNPCC

Errors in DNA replication as well as being exposed to external stimuli like radiation and mutagens may result in mutations in cells' DNA. These modifications in DNA have the potential to cause significant issues such as cell carcinogenesis. There is a way to reverse these alterations in DNA courtesy to the DNA repair machinery. One component is the MMR mechanism, which is carried out by the DNA MMR enzymes and identifies and corrects mistakes made during DNA replication. Using Escherichia coli, this mechanism was first assessed, leading to the identification of the DNA MMR genes (Mut S, Mut L). Six distinct kinds of MMR genes have been identified (hMSH2, hMLH1, hMSH3, hMSH6, hPMS1, and hPMS2). It has been discovered that MMR genes are conserved throughout animals.

It was found that MMR genes are conserved between species, and MMR genes of 6 types (hMSH2,hMLH1, hMSH3, hMSH6, hPMS1, and hPMS2) were identified. These MMR genes were found to be gene involved in the development of HNPCC. These MMR genes have been suggested to function in multisubunit complexes in humans. During DNA replication, hMSH2 recognizes mismatches and repairs them by forming a complex with other MMR proteins. Aberrations of 1 to 2 bases are recognized by the complex of hMSH2 and hMSH6, and deletions and insertions of 2 to 4 bases are recognized by the complex of hMSH2 and hMSH3 and subsequently repaired together in the complex of hMLH1 and hPMS2. , more complexes are being sought.These repair mechanisms need further definition.[11]

DNA mismatch repair (MMR) genes and microsatellite Instability (MSI)

If there is an abnormality in the MMR gene, the base mismatches that occur during DNA replication cannot be corrected, resulting in different lengths of DNA strands. This Phenomenon occurs primarily in regions with multiple base repeats in the human genome And is called microsatellite instability (MSI). The presence of MSI increases the frequency of genetic abnormalities in Genes involved in carcinogenesis. MSI has been identified in 4,444 cases, accounting for approximately 10% of all colorectal cancers. Approximately 25% of MSI-positive colorectal cancers Are variants of HNPCC, suggesting that MSI analysis may be an effective screening method for HNPCC. Among the six MMR genes, germline mutations in the hMLH1 gene on chromosome 3 and the hMSH2 gene on chromosome 2 likely contribute to the majority (approximately 60%) of the HNPCC cases. There is. It remains to be determined whether similar mechanisms or genetic abnormalities are involved in Hebrew type uterine cancer. TGF type IIR, involved in the control of cell proliferation, and BAX, involved in the induction of apoptosis, have been reported as candidate target genes of the MMR machinery.[12],[13]Other candidate target genes include the E2F gene. [14],[15]And TCF-4 genes. 10 Abnormalities in these genes are extremely rare in endometrial cancer, and the target genes that cause abnormalities in the MMR mechanism vary from organ to organ, and it is possible that other specific target genes may be the cause of endometrial cancer. [16]

Clinical characteristics of HNPCC

The exact frequency of HNPCC is unknown due to discrepancies in reporting, but it is believed to be approximately 5D44 among all colorectal cancers. [17] –[23]Clinicopathological features of HNPCC have been reported to include: Genetic; (2) Gene penetrance rate is approximately 85% by age 80. (3) Young onset. (4)

Incidence is higher on the right side of the colorectum. (5) High frequency of mucinous or poorly differentiated cancer cases. (6) Diploidy by cytometric analysis. (7) Marked lymphocytic infiltration. (8) MSI positive. (9) High risk of endometrial cancer, urethral cancer, and colon cancer. (10) Although the reason for the favorable prognosis is not clear, although there are many cases of mucinous carcinoma and poorly differentiated carcinoma, the low rate of lymphocyte infiltration into the tumor and lymphatic metastasis may be contributing factors to the prognosis.[24] Ing. The prognosis forIs good. Recently, it was reported that MMR gene abnormality Is associated with decreased sensitivity to chemotherapy such as cisplatin. [25]

Diagnosis

When the HNPCC Collaborative Group was established in 1991, a meeting was held in Amsterdam and 4,444 diagnostic criteria were developed. The Amsterdam Criteria were the first diagnostic guidelines of their kind, and the purpose of these Was to determine whether a Family should be classified as a potential HNPCC carrier [26] At this point, the gene and its function had not yet been identified and characterized, so decisions were made based on family history and age at onset of colorectal cancer. In response to criticism that the real Amsterdam Criteria were so much comprehensive (e.g., the Included only HNPCC patients/families with Colorectal tumors), it was revised in 1998 to include Extra colonic HNPCC tumors. The version Amsterdam Standard (version II) was developed. Associated cancers (Table 1) [27]. This revision allows for the inclusion of his Individuals and families who were previously excluded based on the original classification. It was previously thought that “Lynch syndrome” consisted of two distinct groups. Lynch syndrome type I is characterized by early-onset (mean age 44 years) hereditary colon cancer (predominantly right-sided (>70%)), whereas Lynch syndrome type II syndrome is characterized by colon cancer In addition, Families with early extracolonic tumors were included. Today, HNPCC Is collectively considered a syndrome .[28]

Treatments

Treatment of patients with HNPCC is based on surgical resection of the colon, proposing the same goals as for sporadic colorectal cancer. Several unique clinical features, previously reported [29],[30] suggests a change in surgical approach. Total abdominal colectomy with ileorectal anastomosis due to the high frequency of synchronous and metachronous colon cancers (40% chance of second cancer after 10 years), primarily located near the rectum (87%). It was suggested it can be carried out. Instead of standard partial resection [29],[30],[31]. The purpose of this procedure is to reduce the risk of second cancers without actually affecting the survival of the primary cancer. In fact, intensive endoscopic follow-up may yield the same results [29],[30]

Surveillance and management in HNPCC:

HNPCC Family Identification Is Very Difficult Because it is important to use a suitable monitoring program, Early detection steps lead to early detection Tumors in asymptomatic families and subsequent tumor development Often reduces mortality. HNPCC appears to be one of the most common risks View colon cancer factors and their frequency Family history should be detailed for all oncological diseases patient. The diagnosis of HNPCC is based on a combination of: Extensive patient and family data. You can also find examples more common in young patients proximally Localized colon cancer. Introduction of genetic markers This will make it easier to identify his HKPCC in the future. Clinical observations suggest progression The transition from adenoma to cancer occurs faster in patients For HNPCC than for sporadic adenoma or sporadic adenoma. Adenoma in familial adenomatous polyposis [32][33]. a Benign adeno causes greater genetic instability. Most HNPCC tumors are in the MA stage. increase the problem The probability of progression to cancer is [34] [35]. therefore. Adenomas are relatively rare, and early treatment of adenomas is possible. Cancer development in HNPCC can be explained as follows. The genetic mechanisms underlying this. between adenomas It does not occur more frequently than in patients with HNPCC. Sporadic cancers have an early onset. Older age, severe dysplasia and internal villous features Inheritance groups: [32] [33] [35]These facts are important factors.

Sporadic Colorectal Cancer:

Around 15% of scattered colorectal tumors too show the MSI-H phenotype [36] and these cases are related with substantial changes within the DNA-mismatched Re-Match of qualities. These substantial changes happen as it were inside Tumor cells and are not present within the germline. The foremost commonly identified substantial alter is hypermethylation Of the hMLH1 promoter [37], which pieces translation Of the quality. As a result, hMLH1 flag-bearer RNA and Protein are not synthesized. Comparative to their genetic partners, these scattered tumors with MSI display a right colonic propensity, mucinous histological highlights, and a conspicuous lymphocytic penetrate. There are a few reasons to consider deciding MSI status for all colorectal tumors. Most vitally, the in general forecast is closely related with her MSI status. Patients with MSI-H tumors have altogether lower mortality rates, not withstanding of tumor arrange [38] this manner, assurance of MSI status progresses the prognostic data given by the classic Dukes organizing framework. The atomic premise for this moved forward result, which too happens in arrange III infection with lymph hub metastases, is obscure. One speculation recommends that transformations moreover amass in qualities vital for tumor cell survival, subsequently starting a “program of self-destruction.” The reaction of colorectal tumors to chemotherapy may depend on their fundamental genotype. A few ponders propose that patients with arrange III MSI-H tumors accepting 5-fluorouracil-based treatment have a survival advantage. Specifically, the 3-year recurrence-free survival rate was 90% for patients with MSI-H tumors versus 32% for patients with microsatellite steady tumors [39]. Another ponder of organize III patients treated with 5-fluorouracil appeared a comparable survival advantage in the patients with MSI-H tumors [40]. Interests, this survival advantage happened as it were in patients with MSI-H tumors who gotten chemotherapy, proposing that MSI may serve as a favorable prognostic marker for patients who gotten adjuvant 5-fluorouracil chemotherapy. Doing. In any case, these perceptions have to be affirmed in bigger considers. The components fundamental the affiliation between destitute repair status and affectability to chemotherapy are obscure. At long last, tumors showing MSI ought to caution clinicians to the plausibility of an unrecognized conclusion of HNPCC.[41].

Conclusion:

It is critical to get it the natural characteristics of endometrial cancer, and the instruments of carcinogenesis are not totally caught on. A few endometrial cancers Are familial tumors, and variations from the norm within the DNA MMR Quality are included in carcinogenesis . Some of these tumors are still misclassified as sporadic, and the genetic incidence appears to be underestimated. All urologists should be aware of this hereditary Syndrome as we need to improve our practices for accurate diagnosis of heart cancer. This allows us to use the 4,444 available clinical criteria to determine her HNPCC risk. Based on this, you can decide whether molecular/genetic testing should be performed. Neither the MSI status of the tumor, young age at cancer diagnosis, nor family history suggestive of atypical or classic HNPCC can identify all germline mutations in Mismatch repair system genes. However, combining MSI and IHC analysis of mismatch repair protein expression in

selected tumor tissues, complemented by DNA sequencing, may be useful in screening for possible mutation carriers and identifying families at risk for HNPCC. May be helpful.

REFERENCES

[1]Warthin AS. Heredity with reference to carcinoma as shown by the study of the cases exanimated in the Pathological laboratory of the University of Michigan. Arch Intern Med 1913;12:546–55.

[2]Lynch HT, Krush AJ. Cancer family "G" revisited: 1895–1970. Cancer 1971;27:1505–11.

[3]Lynch HT, Kimberling W, Albano WA, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II).

I.Clinical description of resource. Cancer 1985;56:934–8.

[4]Lynch HT, Lanspa SJ, Boman BM, et al. Hereditary nonpolyposis colorectal cancer—Lynch syndromes I and II.

Gastroenterol Clin North Am 1988;17:679–712.

[5].Vasen H, Wijnen J, Menko F, Kleibeuker J, Taal B, Griffioen G,Nagengast F, Meijers-Heijboer E, Bertario L, Varesco

L, BisgaardM-L, Mohr J, Fodde R, Meera Khan P. Cancer risk in families withHereditary nonpolyposis colorectal Cancer diagnosed by mutationAnalysis. Gastroenterology 1996;110:1020 –1028.

[6].Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a 5Tiered scheme for standardized Classification of 2.360 unique mismatch repair gene variants in the Insight locus-specific database. Nat Genet. 2014;46(2): 107–115.

[7].. Haraldsdottir S, Rafnar T, Frankel WL, et al. Comprehensive population-wide analysis of lynch Syndrome in Iceland reveals founder Mutations in MSH6 and PMS2. Nat. Commun. 2017;8(1):14755.

[8].Rhyu MS. Molecular mechanisms underlying hereditary Nonpolyposis colorectal carcinoma. I Natl Cancer Inst 1996; Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastroenterology 1995; 109: 1685-99.

[9]Li G, Modrich P. Restoration of mismatch genes to nuclear Extracts of H6 colorectal tumor cells by a Heterodimer of MUTL homologues. PNAS 1995;92:1950-4.

[10].S.J., DEVELLIS, B.M. and SANDLER, R.S., Participation in Fecal occult blood screening: a critical review. Prev. Med., 16, 9-18]

[11] Banno K, Susumu N, Hirao T, et al. (2003) HNPCC and endome-Trial cancer. J Fam Tumor 3:62–67

[12]Markowitz S, Wang J, Myeroff L, et al. (1995) Inactivation of the Type II TGF- receptor in colon cancer cells with microsatellite Instability. Science 268:1336–1338

[13]Rompino N, Yamamoto H, Ionov Y, et al. (1997) Somatic frame- Shift mutation in the BAX gene in colon cancers of the Microsatellite mutator phenotype. Science 275:967–969

[14]Ikeda M, Orimo H, Moriyama H, et al. (1998) Close correlation Between mutation of E2F and hMSH3 genes in colorectal cancers With microsatellite instability. Cancer Res 58:594–598

[15]Souza RF, Yin J, Smolinski KN, et al. (1997) Frequent mutation Of the E2F-4 cell cycle gene in primary human gastrointestinal Tumors. Cancer Res 57:2350–2353

[16]Planck M, Wenngern E, Borg A, et al. (2000) Somatic frameshift Alterations in mononucleotide repeat-coating genes in different Tumor types from an HNPCC family with germline MSH2 mutation. Genes Chromosome Cancer 29:33–39

[17]Lynch HT, Smyrk TC, Watson P, et al. (1993) Genetics, natural History, tumor spectrum, and pathology of hereditary nonpolyposis Colorectal cancer. Gastroenterology 104:1535–1549

[18]Nystrom-Lahti M, Wu Y, Moisio AL, et al. (1996) DNA mismatch Repair gene mutations in 55 kindreds with verified or putative Hereditary non-polyposis colorectal cancer. Hum Mol Genet 5:763–769

[19] Moslein G, Tester DJ, Lindor NM, et al. (1996) Microsatellite Instability and mutation analysis of hMSH2 and hMLH1 in Patients with sporadic, familial and hereditary colorectal cancer.Hum Mol Genet 5:1245–1252

[20] Wu Y, Nystrom-Lahti M, Osinga J (1997) MSH2 and MLH1 mutations in sporadic replication error-positive colorectal carcinoma As assessed by two-dimensional DNA electrophoresis. Genes Chromosome Cancer 18:269–278

[21]. Herfarth K, Kodner IJ, Whelan AJ (1997) Mutations in MLH1 are More frequent than in MSH2 in sporadic colorectal cancers With microsatellite instability. Genes Chromosome Cancer 18:42–49

[22]. Genuardi M, Anti M, Capozzi E, et al. (1998) MLH1 and MSH2 Constitutional mutations in colorectal cancer families not meeting The standard criteria for hereditary nonpolyposis colorectal cancer.Int J Cancer 75:835–839

[23]. Nomura S, Sugano K, Kashiwabara H, et al. (2000) Enhanced Detection of deleterious and other germline mutations of hMSH2 And hMLH1 in Japanese hereditary nonpolyposis colorectal Kindreds. Biochem Biophys Res Commun 271:120–129.

[24]Horii A, Han HJ, Shimada M, et al. (1994) Frequent replication Errors at microsatellite loci in tumors of patients with multiple Primary cancers. Cancer Res 54:3373–3375

[25]Fink D, Nebel S, Aebi S, et al. (1996) The role of DNA mismatch Repair in platinum drug resistance. Cancer Res 56:4881–4886

[26] Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424–5.

[27] Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical Criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–6.

[28] Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261–8.

[29] D'Emilia J., Rodriguez-Bigas M., Petrelli N.J.: The clinical And genetic manifestations of hereditary non-polyposis colo-rectal carcinoma. Am. J. Surg., 169: 368-372, 1995.

[30] Davison Al, Stem H.: Additional specific management problems. In 'Cancer of the Colon, Rectum and Anus', Cohen AM.,Winawer S.J., Friedman M., Gunderson L., Eds., pp.471-489, McGraw-Hill, New York, 1994.

[31] Fitzgibbons R.1. Jr., Lynch H.T., Stanislav G.v., Watson P.A., Lanspa s.r., Marcus J.N., Smyrk T., Kriegler M., Lynch lE: Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II), Ann.Surg., 206: 289-295, 1987.

[32]Love R: Adenomas are precursor lesions for malignant Growth in non-polyposis hereditary carcinoma of the colon And rectum. Surg. Gynecol. Obstet., 162: 8-12, 1986.

[33]Mecklin J.P., Sipponen P., Jarvinen H.J.: Histopathology ofcolorectal carcinomas and adenomas in cancer family syndrome.. Dis. Colon Rectum, 29: 849-853, 1986.

[34]. Jacoby RE, Marshall D.1., Kailas S., Schlack S., Harms B.,Love R: Genetic instability associated with adenoma to carcinoma progression in hereditary non-polyposis colon cancer.Gastroenterology, 109: 73-82, 1995.

[35]Jass LR: Evolution of hereditary bowel cancer. Mutat. Res.,290: 13-25, 1993.

[36]Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M,Et al. The colon cancer burden of genetically defined hereditary nonpolyposis Colon cancer. Gastroenterology. 2001;121:830-8. [PMID: 11606497]

[37]Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence And functional consequences of hMLH1 promoter hypermethylation in colorectall carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870-5. [PMID: 9618505]

[38] Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with Colorectal cancer. N Engl J Med. 2000;342:69-77. [PMID: 10631274]

[39]Hemminki A, Mecklin JP, Ja¨rvinen H, Aaltonen LA, Joensuu H. Micro-Satellite instability is a favorable prognostic indicator in patients with colorectal Cancer receiving chemotherapy. Gastroenterology. 2000;119:921-8. [PMID:11040179]

[40]Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 Alteration and microsatellite instability have predictive value for survival benefit From chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001;7:1343-9. [PMID: 11350904]

[41]7. Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, et al.Mismatch repair gene defects in sporadic colorectal cancers with microsatellite Instability. Nat Genet. 1995;9:48-55. [PMID: 7704024]